Shanghai Junshi Biosciences Co (HKSE:01877) Net Margin % : -74.32% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Shanghai Junshi Biosciences Co's Net Income for the three months ended in Mar. 2024 was HK$-307.5 Mil. Shanghai Junshi Biosciences Co's Revenue for the three months ended in Mar. 2024 was HK$413.7 Mil. Therefore, Shanghai Junshi Biosciences Co's net margin for the quarter that ended in Mar. 2024 was -74.32%.

The historical rank and industry rank for Shanghai Junshi Biosciences Co's Net Margin % or its related term are showing as below:

HKSE:01877' s Net Margin % Range Over the Past 10 Years
Min: -76700.85 Med: -158.01 Max: -17.85
Current: -836.03

HKSE:01877's Net Margin % is ranked worse than
70.54% of 1032 companies
in the Biotechnology industry
Industry Median: -156.25 vs HKSE:01877: -836.03

Shanghai Junshi Biosciences Co Net Margin % Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Net Margin % Chart

Shanghai Junshi Biosciences Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-95.98

-104.44

-17.85

-164.16

-151.85

Shanghai Junshi Biosciences Co Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Margin %	Get a 7-Day Free Trial														-212.98	-109.27	61.28	-	-74.32

Competitive Comparison of Shanghai Junshi Biosciences Co's Net Margin %

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Junshi Biosciences Co's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Net Margin % distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's Net Margin % falls into.

Shanghai Junshi Biosciences Co Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Shanghai Junshi Biosciences Co's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-2495.592	/	1643.457
	=	-151.85 %

Shanghai Junshi Biosciences Co's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin	=	Net Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-307.455	/	413.668
	=	-74.32 %

Shanghai Junshi Biosciences Co (HKSE:01877) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Shanghai Junshi Biosciences Co Net Margin % Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

8SJ:Germany 688180:China

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines